• Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting

    Read more
  • Ryvu Therapeutics Reports Third Quarter 2019 Financial Results

    Read more
  • Ryvu Therapeutics to Present at BIO-Europe 2019

    Read more
  • Ryvu Therapeutics Appoints Chief Medical Officer Setareh Shamsili, M.D., Ph.D., to Executive Management Board

    Read more
  • Ryvu Therapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

    Read more
  • Ryvu Therapeutics and Selvita Announce registration of Corporate Split by the National Court Register of Poland

    Read more
  • Ryvu Announces Shareholder Approval of Corporate Split and New Name of Ryvu Therapeutics for Oncology Development Company

    Read more
  • Ryvu Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

    Read more
  • Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split into Two Separately Listed Companies to Proceed

    Read more
  • Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer

    Read more
  • Selvita to Present at Upcoming Conferences in September

    Read more
  • Selvita announces availability of abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for presentation at 2019 ASCO Annual Meeting and 24th EHA Congress

    Read more
  • Selvita to Present at the UBS 2019 Global Healthcare Conference in New York

    Read more
  • Poster regarding Phase 1/2 study of SEL24/MEN1703 accepted for the ASCO 2019 Annual Meeting

    Read more
  • Selvita to present at the 2019 HCW Global Life Sciences Conference in London

    Read more
  • Selvita to Separate Oncology Therapeutics and Contract Research Business Units into Two Global Companies

    Read more
  • Selvita Announces U.S. FDA Acceptance of Investigational New Drug Application to Commence Clinical Development of SEL120 in the Treatment of Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    Read more
  • Selvita to Present Data from Multiple Oncology Programs at AACR 2019 Annual Meeting

    Read more
  • Selvita to Present at Biotech Showcase 2019 in San Francisco

    Read more
  • Selvita Announces Presentations on CDK8 Inhibitor SEL120 at the 60th American Society of Hematology Annual Meeting

    Read more
  • Selvita to Present New Data from SEL120 Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

    Read more
  • Selvita to present new data from its oncology programs at the upcoming SITC 2018

    Read more
  • Selvita presents new data from SEL120 program during Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice

    Read more
  • Selvita presents at the 25th Annual BioCentury NewsMakers in the Biotech Industry

    Read more
  • Selvita to present new data from its oncology programs at the 6th Annual Immuno-Oncology Summit

    Read more
  • Institute of Hematology and Transfusion Medicine and Selvita publish joint research results on SEL24 potential in Chronic Lymphocytic Leukemia

    Read more
  • Selvita publishes research results on SEL24 in Oncotarget

    Read more
  • Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2018

    Read more
  • Selvita Announces Successful Completion of $41 M Book Building

    Read more
  • FDA lifts Clinical Hold on Selvita’s Phase I/II Clinical Trial with SEL24 in AML

    Read more
  • Selvita researchers and academic collaborators demonstrate the potential of MNK1/2 kinase inhibitors in the treatment of c-Kit positive melanomas

    Read more
  • Selvita Announces Full Clinical Hold on Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

    Read more
  • Selvita and Menarini present together at the European Business Development Conference

    Read more
  • Selvita and The Leukemia & Lymphoma Society Announce Partnership to Advance SEL120 into Phase I for AML Patients

    Read more
  • Institute of Hematology and Transfusion Medicine and Selvita publish joint research results in SEL24 project

    Read more
  • Selvita presents at 18th Drug Discovery Summit in Berlin

    Read more
  • Selvita researchers publish new paper on CDK8 inhibitor SEL120 in Oncotarget

    Read more
  • Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24

    Read more
  • Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

    Read more
  • Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2017

    Read more
  • Selvita researchers publish MNK inhibitors review in Current Medicinal Chemistry

    Read more
  • Selvita to present at Biotech Showcase 2017 in San Francisco

    Read more
  • Selvita presents posters at 2016 EORTC-NCI-AACR Symposium

    Read more
  • FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML

    Read more
  • FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML

    Read more
  • Epidarex Capital Creates Nodthera Limite

    Read more
  • Selvita epigenetic project is the first Polish drug target program selected by EU Lead Factory

    Read more
  • Selvita will present at the 18th Annual BIO CEO & Investor Conference 2016

    Read more
  • Selvita wins the European Rising Star Award

    Read more
  • The most recent data from Selvita’s SEL24 to be presented at the 57th ASH Annual Meeting & Exposition

    Read more
  • Merck and Selvita Announce Drug Discovery Collaboration

    Read more
  • Selvita launches new company – bioinformatics and personalized medicine focused Ardigen

    Read more
  • H3 Biomedicine and Selvita Extend Precision Cancer Medicines Collaboration

    Read more
  • Selvita receives the Economic Award of the President of Poland

    Read more
  • Selvita initiates IND-enabling Studies for its first-in-class PIM/FLT3 inhibitor

    Read more
  • Felicitex Therapeutics and Selvita initiate strategic collaboration to target cancer quiescence

    Read more
  • Selvita and H3 Biomedicine will present at the Drug Discovery USA Congress 2014

    Read more
  • New data from Selvita’s SEL24 will be presented by Institute of Hematology and Transfusion Medicine (IHT) at the ASH Meeting on Lymphoma Biology 2014

    Read more
    • Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting

      Read more
    • Ryvu Therapeutics Reports Third Quarter 2019 Financial Results

      Read more
    • Ryvu Therapeutics to Present at BIO-Europe 2019

      Read more
    • Ryvu Therapeutics Appoints Chief Medical Officer Setareh Shamsili, M.D., Ph.D., to Executive Management Board

      Read more
    • Ryvu Therapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

      Read more
    • Ryvu Therapeutics and Selvita Announce registration of Corporate Split by the National Court Register of Poland

      Read more
    • Ryvu Announces Shareholder Approval of Corporate Split and New Name of Ryvu Therapeutics for Oncology Development Company

      Read more
    • Ryvu Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

      Read more
    • Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split into Two Separately Listed Companies to Proceed

      Read more
    • Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer

      Read more
    • Selvita to Present at Upcoming Conferences in September

      Read more
    • Selvita announces availability of abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for presentation at 2019 ASCO Annual Meeting and 24th EHA Congress

      Read more
    • Selvita to Present at the UBS 2019 Global Healthcare Conference in New York

      Read more
    • Poster regarding Phase 1/2 study of SEL24/MEN1703 accepted for the ASCO 2019 Annual Meeting

      Read more
    • Selvita to present at the 2019 HCW Global Life Sciences Conference in London

      Read more
    • Selvita to Separate Oncology Therapeutics and Contract Research Business Units into Two Global Companies

      Read more
    • Selvita Announces U.S. FDA Acceptance of Investigational New Drug Application to Commence Clinical Development of SEL120 in the Treatment of Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

      Read more
    • Selvita to Present Data from Multiple Oncology Programs at AACR 2019 Annual Meeting

      Read more
    • Selvita to Present at Biotech Showcase 2019 in San Francisco

      Read more
    • New data from Selvita’s SEL24 will be presented by Institute of Hematology and Transfusion Medicine (IHT) at the ASH Meeting on Lymphoma Biology 2014

      Read more
    • Selvita Announces Presentations on CDK8 Inhibitor SEL120 at the 60th American Society of Hematology Annual Meeting

      Read more
    • Selvita to Present New Data from SEL120 Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

      Read more
    • Selvita to present new data from its oncology programs at the upcoming SITC 2018

      Read more
    • Selvita presents new data from SEL120 program during Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice

      Read more
    • Selvita presents at the 25th Annual BioCentury NewsMakers in the Biotech Industry

      Read more
    • Selvita to present new data from its oncology programs at the 6th Annual Immuno-Oncology Summit

      Read more
    • Institute of Hematology and Transfusion Medicine and Selvita publish joint research results on SEL24 potential in Chronic Lymphocytic Leukemia

      Read more
    • Selvita publishes research results on SEL24 in Oncotarget

      Read more
    • Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2018

      Read more
    • Selvita Announces Successful Completion of $41 M Book Building

      Read more
    • FDA lifts Clinical Hold on Selvita’s Phase I/II Clinical Trial with SEL24 in AML

      Read more
    • Selvita researchers and academic collaborators demonstrate the potential of MNK1/2 kinase inhibitors in the treatment of c-Kit positive melanomas

      Read more
    • Selvita Announces Full Clinical Hold on Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

      Read more
    • Selvita and Menarini present together at the European Business Development Conference

      Read more
    • Selvita and The Leukemia & Lymphoma Society Announce Partnership to Advance SEL120 into Phase I for AML Patients

      Read more
    • Institute of Hematology and Transfusion Medicine and Selvita publish joint research results in SEL24 project

      Read more
    • Selvita presents at 18th Drug Discovery Summit in Berlin

      Read more
    • Selvita researchers publish new paper on CDK8 inhibitor SEL120 in Oncotarget

      Read more
    • Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24

      Read more
    • Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

      Read more
    • Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2017

      Read more
    • Selvita researchers publish MNK inhibitors review in Current Medicinal Chemistry

      Read more
    • Selvita to present at Biotech Showcase 2017 in San Francisco

      Read more
    • Selvita presents posters at 2016 EORTC-NCI-AACR Symposium

      Read more
    • FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML

      Read more
    • FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML

      Read more
    • Epidarex Capital Creates Nodthera Limite

      Read more
    • Selvita epigenetic project is the first Polish drug target program selected by EU Lead Factory

      Read more
    • Selvita will present at the 18th Annual BIO CEO & Investor Conference 2016

      Read more
    • Selvita wins the European Rising Star Award

      Read more
    • The most recent data from Selvita’s SEL24 to be presented at the 57th ASH Annual Meeting & Exposition

      Read more
    • Merck and Selvita Announce Drug Discovery Collaboration

      Read more
    • Selvita launches new company – bioinformatics and personalized medicine focused Ardigen

      Read more
    • H3 Biomedicine and Selvita Extend Precision Cancer Medicines Collaboration

      Read more
    • Selvita receives the Economic Award of the President of Poland

      Read more
    • Selvita initiates IND-enabling Studies for its first-in-class PIM/FLT3 inhibitor

      Read more
    • Felicitex Therapeutics and Selvita initiate strategic collaboration to target cancer quiescence

      Read more
    • Selvita and H3 Biomedicine will present at the Drug Discovery USA Congress 2014

      Read more
    • New data from Selvita’s SEL24 will be presented by Institute of Hematology and Transfusion Medicine (IHT) at the ASH Meeting on Lymphoma Biology 2014

      Read more